← All trials
NCT07215767
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2025
- Primary completion
- Jul 31, 2026
- Completion date
- Jul 31, 2026
- First posted
- Oct 10, 2025
- Last posted
- Nov 4, 2025
- Enrollment
- 850
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Healeon Medical IncLead sponsor
- Salus ResearchOfficial
- All Sum Research Center Ltd.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.